- $766.88m
- $537.68m
- $0.58m
Brief: Icosavax Announces Positive Topline Interim Phase 1/1B Results For VLP Vaccine Candidate IVX-121 Against Rsv
Icosavax jumps with focus on upcoming RSV vaccine data
All eyes on Icosavax's RSV vaccine data after COVID-19 shot setback - William Blair
Brief: Icosavax Reports Fourth Quarter And Full Year 2021 Financial Results
U.S. RESEARCH ROUNDUP- Beyond Meat, Kennametal, McDonald's
Diagnostics, OppFi Inc
U.S. STOCKS ON THE MOVE-Icosavax, MEI Pharma, Clever Leaves
Brief: Icosavax Announces Topline Interim Phase 1/2 Results For Ivx-411 Against Sars-Cov-2
Icosavax drops 20% after early-stage data from COVID-19 vaccine candidate disappoints
Covid: 19 vaccine deliveries to reach up to 5.5 billion doses in 2022 - Jefferies
Brief: Icosavax Provides Corporate Update And Anticipated Milestones For 2022
Brief: Icosavax Appoints Dr. John Shiver To Board Of Directors
U.S. RESEARCH ROUNDUP-Akamai Technologies, Metacrine, Vaxcyte
Brief: Icosavax Reports Q3 2021 Financial Results
Brief: Icosavax Reports Second Quarter 2021 Financial Results And Provides Corporate Update
Brief: Icosavax Starts Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
U.S. RESEARCH ROUNDUP-Duolingo, Icosavax, Nuvalent
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:51 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM